Page last updated: 2024-10-30

lomustine and Abnormalities, Autosome

lomustine has been researched along with Abnormalities, Autosome in 10 studies

Research Excerpts

ExcerptRelevanceReference
" First- and second-line therapeutics for glioblastomas are alkylating agents, including the chloroethylating nitrosoureas (CNU) lomustine, nimustine, fotemustine, and carmustine."3.83Targeting Homologous Recombination by Pharmacological Inhibitors Enhances the Killing Response of Glioblastoma Cells Treated with Alkylating Drugs. ( Berte, N; Borgmann, K; Kaina, B; Nikolova, T; Piecha, N; Piée-Staffa, A; Wang, M, 2016)
"Neither the number of chromosomal aberrations nor the number of SCE were affected by the addition of 1000 micrograms/ml taurine to the culture medium."1.28Genotoxicity of tauromustine, a new water soluble taurine-based nitrosourea. I. Mutagenic and clastogenic activity of tauromustine in vitro. ( Hartley-Asp, B, 1992)

Research

Studies (10)

TimeframeStudies, this research(%)All Research%
pre-19904 (40.00)18.7374
1990's2 (20.00)18.2507
2000's2 (20.00)29.6817
2010's2 (20.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Berte, N1
Piée-Staffa, A1
Piecha, N1
Wang, M1
Borgmann, K1
Kaina, B1
Nikolova, T1
Idbaih, A1
Dalmasso, C1
Kouwenhoven, M1
Jeuken, J1
Carpentier, C1
Gorlia, T1
Kros, JM2
French, P1
Teepen, J1
Broët, P1
Delattre, O1
Mokhtari, K1
Sanson, M1
Delattre, JY1
van den Bent, M1
Hoang-Xuan, K1
Buckner, JC1
Gesme, D1
O'Fallon, JR1
Hammack, JE1
Stafford, S1
Brown, PD1
Hawkins, R1
Scheithauer, BW1
Erickson, BJ1
Levitt, R1
Shaw, EG1
Jenkins, R1
van den Bent, MJ1
Looijenga, LH1
Langenberg, K1
Dinjens, W1
Graveland, W1
Uytdewilligen, L1
Sillevis Smitt, PA1
Jenkins, RB1
Gebhart, E1
Lösing, J1
Wopfner, F1
Lambert, B1
Ringborg, U1
Lindblad, A1
Hartley-Asp, B1
Koldamova, RP1
Lefterov, IM1
Pedersen-Bjergaard, J1
Osterlind, K1
Hansen, M1
Philip, P1
Pedersen, AG1
Hansen, HH1
Vyas, RC1
Adhvaryu, SG1
Shah, VC1

Clinical Trials (2)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
PHASE III STUDY OF ADJUVANT PROCARBAZINE, CCNU AND VINCRISTINE CHEMOTHERAPY IN PATIENTS WITH HIGHLY ANAPLASTIC OLIGODENDROGLIOMA[NCT00002840]Phase 3350 participants (Anticipated)Interventional1996-08-31Completed
PHASE II STUDY OF PREIRRADIATION PCV CHEMOTHERAPY IN PATIENTS WITH SUPRATENTORIAL LOW-GRADE GLIOMAS[NCT00002806]Phase 243 participants (Actual)Interventional1996-07-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trials

2 trials available for lomustine and Abnormalities, Autosome

ArticleYear
Genomic aberrations associated with outcome in anaplastic oligodendroglial tumors treated within the EORTC phase III trial 26951.
    Journal of neuro-oncology, 2011, Volume: 103, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Brain Neoplasms; Chr

2011
Phase II trial of procarbazine, lomustine, and vincristine as initial therapy for patients with low-grade oligodendroglioma or oligoastrocytoma: efficacy and associations with chromosomal abnormalities.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2003, Jan-15, Volume: 21, Issue:2

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Chromosome Aber

2003

Other Studies

8 other studies available for lomustine and Abnormalities, Autosome

ArticleYear
Targeting Homologous Recombination by Pharmacological Inhibitors Enhances the Killing Response of Glioblastoma Cells Treated with Alkylating Drugs.
    Molecular cancer therapeutics, 2016, Volume: 15, Issue:11

    Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Cell Line, Tumor; Cell Survival; Chromosome A

2016
Chromosomal anomalies in oligodendroglial tumors are correlated with clinical features.
    Cancer, 2003, Mar-01, Volume: 97, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chromosome Aberrations; Chromosomes

2003
Chromosome studies on lymphocytes of patients under cytostatic therapy. I. Conventional chromosome studies in cytostatic interval therapy.
    Human genetics, 1980, Volume: 55, Issue:1

    Topics: Adult; Aged; Antineoplastic Agents; Chromosome Aberrations; Chromosomes; Drug Administration Schedul

1980
Prolonged increase of sister-chromatid exchanges in lymphocytes of melanoma patients after CCNU treatment.
    Mutation research, 1979, Volume: 59, Issue:2

    Topics: Chromosome Aberrations; Chromosomes, Human; Crossing Over, Genetic; Humans; Lomustine; Lymphocytes;

1979
Genotoxicity of tauromustine, a new water soluble taurine-based nitrosourea. I. Mutagenic and clastogenic activity of tauromustine in vitro.
    Mutagenesis, 1992, Volume: 7, Issue:6

    Topics: Antineoplastic Agents; Cell Cycle; Chromosome Aberrations; Humans; In Vitro Techniques; Lomustine; L

1992
Synergistic effect of CCNU and bleomycin on human lymphocytes exposed at late G1 and G2 states of the cell cycle.
    Mutation research, 1991, Volume: 260, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cell Cycle; Chromosome Aberrations; Drug

1991
Acute nonlymphocytic leukemia, preleukemia, and solid tumors following intensive chemotherapy of small cell carcinoma of the lung.
    Blood, 1985, Volume: 66, Issue:6

    Topics: Acute Disease; Carcinoma, Small Cell; Chromosome Aberrations; Chromosome Disorders; Cyclophosphamide

1985
Effects of CCNU therapy on human chromosomes.
    Mutation research, 1988, Volume: 206, Issue:2

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chromosome Aberrations; Female; Humans; Lomust

1988